Lindsey Shapiro, PhD,  science writer—

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Early diagnosis is focus of 2025 World PH Day

On May 5, more than 80 organizations around the world will join to raise awareness of pulmonary hypertension (PH), a serious but often under-recognized cardiovascular disease affecting more than 75 million people worldwide. World Pulmonary Hypertension Day, an annual event spearheaded by PHAEurope, also aims to promote…

TX45 improves heart function, blood flow in PH-HFpEF

A single dose of the investigational therapy TX45 improved heart function and blood flow, or hemodynamics, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to interim results from a Phase 1b clinical trial. The part of the study involving PH-HFpEF patients is completely…

Rising immune cell ratio can risk survival with CKD-related PH

Elevated blood levels of an inflammatory biomarker called the neutrophil-to-lymphocyte ratio (NLR) were associated with a higher risk of death among people with pulmonary hypertension (PH) related to chronic kidney disease (CKD), according to a recent report. “NLR, which is a convenient and inexpensive parameter, may be a novel…

PAH treatment Uptravi leads to improvements, registry data show

Most adults with pulmonary arterial hypertension (PAH) who switched to Uptravi (selexipag) from other medications in its class achieved stabilization or a lessening of disease severity, according to an analysis of real-world treatment data from the SPHERE registry. Clinical outcomes were also generally good for Uptravi-treated PAH patients…